Company news

Neovasc Inc news in 2019

Neovasc Inc's news releases, calls and decks from 2019, newest first.

View company

Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)

December 31, 2019

Neovasc Reducer(TM) Featured In National Geographic Magazine

December 17, 2019

Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019

December 4, 2019

Neovasc Reducer(TM) Featured In FOCUS Magazine

November 26, 2019

Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

November 22, 2019

Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019

November 19, 2019

Neovasc Reducer(TM) Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

November 12, 2019

Neovasc Announces Third Quarter 2019 Financial Results

November 7, 2019

Neovasc to Participate in Stifel 2019 Healthcare Conference and Cannacord Genuity 13th Annual MedTech & Diagnostics Forum

November 6, 2019

Neovasc to Provide Update on TF/TS Tiara Program at PCR Valves 2019

November 5, 2019

Neovasc to Submit Full PMA Application for Neovasc Reducer(TM) in 2019

November 1, 2019

Neovasc to Participate in the 28th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019

October 30, 2019

Neovasc to Announce Third Quarter 2019 Financial Results on Thursday, November 7, 2019

October 25, 2019

Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Sponsored Session at the 40th Annual National Congress of the Italian Society of Interventional Cardiology

October 22, 2019

Neovasc Retains Westwicke, ICR for Integrated Communications Counsel

October 16, 2019

Neovasc Announces Notice of US Patent Granted for Tiara(TM) Transcatheter Device for Treatment of Severe Mitral Regurgitation

October 15, 2019

Neovasc's Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference

September 30, 2019

Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina to be Featured at TCT 2019 Conference

September 23, 2019

Neovasc Announces Changes to its Board of Directors

September 16, 2019

Neovasc to Present at the H.C. Wainwright 21st Annual Global Investment Conference

September 4, 2019

The European Society of Cardiology Includes Neovasc Reducer(TM) for the Treatment of Refractory Angina in the European Practice Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes

September 3, 2019

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

August 22, 2019

Neovasc Announces Second Quarter 2019 Financial Results

August 7, 2019

Neovasc to Attend Canaccord Genuity 39th Annual Growth Conference

August 5, 2019

Neovasc to Announce Second Quarter 2019 Financial Results on Wednesday, August 7th

August 2, 2019

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

July 17, 2019

Neovasc Provides Further Update on Reducer(TM) Program for Treatment of Refractory Angina

July 16, 2019

Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves

July 15, 2019

Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

July 12, 2019

Neovasc Announces Effective Date of Share Consolidation

June 28, 2019

Neovasc Announces Presentations on Tiara(TM) for Treatment of Mitral Regurgitation and Reducer(TM) for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference

June 27, 2019

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

June 25, 2019

Tiara(TM) Featured in Presentation at 11th Annual TVT 2019

June 17, 2019

Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

June 7, 2019

New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

May 23, 2019

Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer(TM) in a Peer Reviewed Article in the International Journal of Cardiology

May 22, 2019

Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

May 15, 2019

Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

May 14, 2019

/C O R R E C T I O N from Source -- Neovasc Inc./

May 9, 2019

Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer(TM)

May 6, 2019

Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

May 3, 2019

Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

April 26, 2019

Neovasc Announces Resolution of Last Remaining Active Litigation

April 17, 2019

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer(TM) Improves Diastolic Function in patients suffering from severe angina

April 17, 2019

Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

March 21, 2019

Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara(TM)

March 21, 2019

Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

March 19, 2019

Neovasc Announces Closing of $5 Million Public Offering of Common Shares

March 15, 2019

Neovasc Completes Successful Quality System Surveillance Audit

March 14, 2019

Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

March 13, 2019

Older news releases →